As of 2025-07-06, the Intrinsic Value of Transgene Biotek Ltd (526139.BO) is (2.80) INR. This 526139.BO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 4.85 INR, the upside of Transgene Biotek Ltd is -157.70%.
The range of the Intrinsic Value is (3.97) - (2.53) INR
Based on its market price of 4.85 INR and our intrinsic valuation, Transgene Biotek Ltd (526139.BO) is overvalued by 157.70%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (3.97) - (2.53) | (2.80) | -157.7% |
| DCF (Growth 10y) | (2.61) - (4.20) | (2.91) | -159.9% |
| DCF (EBITDA 5y) | (2.39) - (2.69) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (2.49) - (2.88) | (1,234.50) | -123450.0% |
| Fair Value | -2.23 - -2.23 | -2.23 | -146.00% |
| P/E | (2.30) - (1.91) | (2.44) | -150.4% |
| EV/EBITDA | (2.41) - (2.26) | (2.32) | -147.8% |
| EPV | 3.89 - 7.53 | 5.71 | 17.7% |
| DDM - Stable | (0.59) - (2.38) | (1.48) | -130.6% |
| DDM - Multi | (0.47) - (1.58) | (0.74) | -115.2% |
| Market Cap (mil) | 367.48 |
| Beta | 0.92 |
| Outstanding shares (mil) | 75.77 |
| Enterprise Value (mil) | 509.84 |
| Market risk premium | 8.31% |
| Cost of Equity | 10.96% |
| Cost of Debt | 5.50% |
| WACC | 8.95% |